Thermo Fisher Scientific TMO has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 3 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $632.5, along with a high estimate of $670.00 and a low estimate of $600.00. This upward trend is apparent, with the current average reflecting a 4.7% increase from the previous average price target of $604.10.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Thermo Fisher Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Lowers | Equal-Weight | $600.00 | $615.00 |
| Tycho Peterson | Jefferies | Raises | Buy | $650.00 | $600.00 |
| Rajesh Kumar | HSBC | Raises | Buy | $670.00 | $660.00 |
| Rachel Vatnsdal | JP Morgan | Raises | Overweight | $650.00 | $600.00 |
| Luke Sergott | Barclays | Raises | Equal-Weight | $615.00 | $590.00 |
| Justin Bowers | Deutsche Bank | Raises | Buy | $610.00 | $600.00 |
| Catherine Schulte | Baird | Lowers | Outperform | $620.00 | $621.00 |
| Rajesh Kumar | HSBC | Raises | Buy | $660.00 | $630.00 |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $640.00 | $550.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $610.00 | $575.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Thermo Fisher Scientific. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Thermo Fisher Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Thermo Fisher Scientific's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Thermo Fisher Scientific analyst ratings.
About Thermo Fisher Scientific
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Key Indicators: Thermo Fisher Scientific's Financial Health
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Challenges: Thermo Fisher Scientific's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -3.41%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Thermo Fisher Scientific's ROE stands out, surpassing industry averages. With an impressive ROE of 2.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.36%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.78.
The Significance of Analyst Ratings Explained
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
